SCHEMBL4602365

SCHEMBL4602365

CC(C)(O)c1ccc(OCc2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.61
CYP1A2 P05177 1/20 0.61
PTGS1 P23219 1/20 0.61
SLC6A2 P23975 1/20 0.61
CYP2C19 P33261 1/20 0.61
PTGS2 P35354 1/20 0.61
SLC6A3 Q01959 1/20 0.61
HIF1A Q16665 1/20 0.61
HDAC6 Q9UBN7 1/20 0.61
MAOB P27338 4/20 0.56
MAPT P10636 2/20 0.55
GAA P10253 1/20 0.55
MAOA P21397 1/20 0.55
RAB9A P51151 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
NR4A2 P43354 2/20 0.54
NR4A1 P22736 1/20 0.54
NR4A3 Q92570 1/20 0.54
RXRA P19793 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24533723 0.91 APP (0.61) MAOBNR4A2RXRARXRBAPP
SCHEMBL24533725 0.88 F2 (0.53) MAOBMAOARAB9ASMN1; SMN2NR4A2
SCHEMBL7989351 0.86 LMNA (0.58) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL17024339 0.86 LMNA (0.58) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL12601246 0.85 ALOX5 (0.63) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL10013799 0.85 LMNA (0.60) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL16016779 0.85 LMNA (0.60) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL24533757 0.85 APP (0.50) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL419050 0.85 APP (0.69) LMNACYP1A2PTGS1SLC6A2CYP2C19
SCHEMBL5164170 0.84 MEN1 (0.51) LMNACYP1A2PTGS1SLC6A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11447485-B2 Class of bifunctional compounds with quanternary ammonium salt structure BEIJING SHOWBY PHARMACEUTICAL CO., LTD. (CN) 2022-09-20 US disclosed
CN-110087729-B Bifunctional compound with quaternary ammonium salt structure 北京硕佰医药科技有限责任公司 2022-04-05 CN disclosed
EP-3556435-B1 CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE BEIJING SHOWBY PHARMACEUTICAL CO LTD (CN) 2020-10-28 EP disclosed
EP-3556435-A1 CLASS OF BIFUNCTIONAL COMPOUNDS WITH QUATERNARY AMMONIUM SALT STRUCTURE Beijing Showby Pharmaceutical Co., Ltd. (CN) 2019-10-23 EP disclosed
EP-0979819-B1 Process for the production of substituted 3-hydroxypiperidines SPEEDEL PHARMA AG (CH) 2008-04-23 EP disclosed
EP-0979824-B1 Process for the preparation of substituted piperidine-epoxides HOFFMANN LA ROCHE (CH) 2004-10-06 EP disclosed
CN-1161335-C Method for preparing substituted piperidine - 2004-08-11 CN disclosed
CN-1111534-C Method for preparing substituted piperidine-epoxide HOFFMANN LA ROCHE (CH) 2003-06-18 CN disclosed
US-6274735-B1 RENIN INHIBITORS HOFFMANN-LA ROCHE INC. 2001-08-14 US disclosed
US-6268499-B1 USEFUL AS RENIN INHIBITORS HOFFMAN-LA ROCHE INC. 2001-07-31 US disclosed
CN-1245800-A Method for preparing substituted piperidine HOFFMANN LA ROCHE (CH) 2000-03-01 CN disclosed
CN-1245805-A Method for preparing substituted piperidine-epoxide HOFFMANN LA ROCHE (CH) 2000-03-01 CN disclosed
EP-0979824-A1 Process for the preparation of substituted piperidine-epoxides F. HOFFMANN-LA ROCHE AG (CH) 2000-02-16 EP disclosed
EP-0979819-A1 Process for the production of substituted 3-hydroxypiperidines F. HOFFMANN-LA ROCHE AG (CH) 2000-02-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11447485-B2 Class of bifunctional compounds with quanternary ammonium salt structure AGTR2, AGTR1, ADRB2 LMNA 2541/4885CYP1A2 585/4885PTGS1 2581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.